
June 2 (Reuters) - Trevi Therapeutics Inc TRVI.O:
TREVI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE 2B CORAL TRIAL OF HADUVIO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS CHRONIC COUGH
TREVI THERAPEUTICS INC - TO REQUEST END-OF-PHASE 2 MEETING WITH FDA, PHASE 3 IN 2026
TREVI THERAPEUTICS INC - HADUVIO MET PRIMARY ENDPOINT , ACHIEVES -43.3% PLACEBO-ADJUSTED CHANGE IN COUGH FREQUENCY AT 108 MG BID
TREVI THERAPEUTICS INC - HADUVIO WELL-TOLERATED WITH SIMILAR DISCONTINUATION RATES TO PLACEBO